A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma zdiagnozowanego chłoniaka rozlanego z dużych komórek B (DLBCL).
- •Grupa 1: Pacjent jest w wieku 80 lat lub starszy, albo młodszy, ale ma choroby współistniejące i nie toleruje standardowego leczenia (jak CHOP).
- •Grupa 2: Pacjent ma zdiagnozowanego DLBCL, ale nie kwalifikuje się do grupy pacjentów osłabionych.
- •Grupa 3: Chłoniak powrócił lub nie zareagował na wcześniejsze leczenie.
✗ Disqualifies
- •Pacjent obecnie uczestniczy lub planuje uczestniczyć w innym badaniu klinicznym.
- •Lekarz prowadzący uzna, że coś innego sprawia, że pacjent nie nadaje się do tego badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
Peking Union Medical College Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Hospital of Ministry of Health
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
Xiangya Hospital of Centre-South University
Changsha, China
Third Xiangya Hospital of Central South University
Changsha, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, China
Zhujiang Hospital, Southern Medical University
Guangzhou, China
Guizhou Cancer Hospital
Guiyang, China
Hainan Cancer Hospital
Haikou, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China
Jiangxi Cancer Hospital
Nanchang, China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, China
Jiangsu Cancer Hospital
Nanjing, China
The Affiliated Hospital Of Qingdao University
Qingdao, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
Tongji Hospital of Tongji University
Shanghai, China
China Medical University (CMU) First Affiliated Hospital
Shenyang, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Shanxi Province Cancer Hospital
Taiyuan, China
Tianjin Medical University General Hospital
Tianjin, China
Tianjin Cancer Hospital
Tianjin, China
Xinjiang Medical University Cancer Hospital
Ürümqi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Wuxi People's Hospital
Wuxi, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Henan Cancer Hospital
Zhengzhou, China
Trial contact
ML44616 https://forpatients.roche.com/
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.